Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia
To improve mechanism-based pharmacotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), we analyzed mode of action and potential synergies of inotuzumab ozogamicin (INO) with the p38 kinase inhibitor BIRB 796 and the BCL2-specific BH3 mimetic venetoclax (VEN) in BCP-ALL cell lines a...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Ferrata Storti Foundation
2026-06-01
|
| Edice: | Haematologica |
| On-line přístup: | https://haematologica.org/article/view/14257 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|